AB Science Secures EMA Approval for Masivet Shelf-Life Extension
AB Science SA has made significant strides with the European Medicine Agency (EMA) granting approval for an extension in the shelf-life of its veterinary product, Masivet. This is a remarkable achievement for the company as they increase the shelf-life from 36 to 48 months. The newly approved shelf-life applies specifically to the 50mg tablet strength of Masivet, which is widely distributed across EU markets.
The Importance of Masivet in Veterinary Medicine
Masivet is notably recognized for its critical role in treating non-resectable dog mast cell tumors, particularly those classified as Grade 2 or 3, featuring confirmed mutations in the c-kit tyrosine kinase receptor. This veterinary medicine ensures effective treatment strategies remain accessible for veterinarians across Europe, allowing them to provide optimal care to their canine patients.
Enhancing Flexibility in Treatment Options
The approval for an extended shelf-life offers greater flexibility for both AB Science and veterinary practitioners. It enables the adjustment of inventory based on real-time demand factors, mitigating the risks associated with product expiration while ensuring consistent treatment options remain available for dogs suffering from these serious health complications.
About AB Science
Founded in 2001, AB Science specializes in the innovative development of protein kinase inhibitors (PKIs). This unique approach allows the company to address high unmet medical needs across various diseases, focusing on conditions that may pose significant risks to life, such as cancer and serious neurological disorders. Despite the challenges faced in these sectors, AB Science's commitment to research has facilitated the establishment of a robust portfolio, spearheading efforts not only in veterinary medicine but also within human therapeutic applications.
Masitinib: The Lead Compound
AB Science's primary compound, masitinib, has proven instrumental in the veterinary market and is fundamentally being explored for applications in oncology, neurological diseases, inflammatory conditions, and viral infections in human medicine. The ongoing research and development contribute to a broader fight against critical health challenges, aiming to enhance survival rates and improve quality of life.
Company Overview and Future Directions
With its headquarters located in Paris, France, and listing on Euronext Paris (ticker: AB), the company is poised for continued growth as it explores the future of treatment across multiple medical disciplines. They are committed to frontline research, ensuring innovative solutions are available to treat some of the most pressing health issues.
Frequently Asked Questions
What is the significance of the shelf-life extension for Masivet?
The extension allows for better inventory management and ensures the continued availability of the product for effective treatment of canine mast cell tumors.
How does Masivet work in treating dog tumors?
Masivet targets specific mutations in cancer cells, providing a targeted therapy for non-resectable mast cell tumors in dogs.
What diseases does AB Science focus on?
AB Science specializes in diseases with high unmet medical needs including oncology and neurological disorders, emphasizing innovative treatment solutions.
Where is AB Science located?
AB Science is headquartered in Paris, France, and is publicly listed on Euronext Paris.
What are protein kinase inhibitors?
Protein kinase inhibitors are a class of medications designed to block specific enzymes involved in cell signaling pathways, which are important in cancer and other serious diseases.
